|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu
W, Giri DD, Viale A, Olshen AB, Gerald WL and Massagué J: Genes
that mediate breast cancer metastasis to lung. Nature. 436:518–524.
2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bacalbasa N, Balescu I, Ilie V, Florea R,
Sorop A, Brasoveanu V, Brezean I, Vilcu M, Dima S and Popescu I:
The impact on the long-term outcomes of hormonal status after
hepatic resection for breast cancer liver metastases. In Vivo.
32:1247–1253. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Oruç Z, Kaplan MA and Arslan Ç: An update
on the currently available and future chemotherapy for treating
bone metastases in breast cancer patients. Expert Opin
Pharmacother. 19:1305–1316. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bos PD, Zhang XH, Nadal C, Shu W, Gomis
RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA and
Massagué J: Genes that mediate breast cancer metastasis to the
brain. Nature. 459:1005–1009. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Liang RB, Yu K, Wu JL, Liu JX, Lin Q, Li
B, Zhang YQ, Ge QM, Li QY, Shu HY and Shao Y: Risk factors and
their diagnostic values for ocular metastases in invasive ductal
carcinoma. Cancer Med. 10:824–832. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Georgalas I, Paraskevopoulos T,
Koutsandrea C, Kardara E, Malamos P, Ladas D and Papaconstantinou
D: Ophthalmic metastasis of breast cancer and ocular side effects
from breast cancer treatment and management: Mini review. Biomed
Res Int. 2015(574086)2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Reddy S, Kurli M, Tena LB and Finger PT:
PET/CT imaging: Detection of choroidal melanoma. Br J Ophthalmol.
89:1265–1269. 2005.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Razek AA and Elkhamary S: MRI of
retinoblastoma. Br J Radiol. 84:775–784. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shao YH, Tsai K, Kim S, Wu YJ and Demissie
K: Exposure to tomographic scans and cancer risks. JNCI Cancer
Spectr. 4(pkz072)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Martin TA, Ye L, Sanders AJ, Lane J and
Jiang WG: Cancer Invasion and Metastasis: Molecular and Cellular
Perspective. In: Madame Curie Bioscience Database [Internet].
Landes Bioscience, Austin, TX, 2000-2013.
|
|
12
|
Wagner PD and Srivastava S: New paradigms
in translational science research in cancer biomarkers. Transl Res.
159:343–353. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shimetani N: Status quo of tumor markers
and important points in medical practice. Rinsho Byori.
51:1216–1220. 2003.PubMed/NCBI(In Japanese).
|
|
14
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Duffy MJ, Evoy D and McDermott EW: CA
15-3: Uses and limitation as a biomarker for breast cancer. Clin
Chim Acta. 411:1869–1874. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rahn JJ, Dabbagh L, Pasdar M and Hugh JC:
The importance of MUC1 cellular localization in patients with
breast carcinoma: An immunohistologic study of 71 patients and
review of the literature. Cancer. 91:1973–1982. 2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hayes DF, Zurawski VR and Kufe DW:
Comparison of circulating CA15-3 and carcinoembryonic antigen
levels in patients with breast cancer. J Clin Oncol. 4:1542–1550.
1986.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Stieber P, Molina R, Chan DW, Fritsche HA,
Beyrau R, Bonfrer JM, Filella X, Gornet TG, Hoff T, Jäger W, et al:
Evaluation of the analytical and clinical performance of the
Elecsys CA 15-3 immunoassay. Clin Chem. 47:2162–2164.
2001.PubMed/NCBI
|
|
19
|
Stieber P, Molina R, Chan DW, Fritsche HA,
Beyrau R, Bonfrer JM, Filella X, Gornet TG, Hoff T, Jäger W, et al:
Clinical evaluation of the Elecsys CA 15-3 test in breast cancer
patients. Clin Lab. 49:15–24. 2003.PubMed/NCBI
|
|
20
|
Bon GG, von Mensdorff-Pouilly S, Kenemans
P, van Kamp GJ, Verstraeten RA, Hilgers J, Meijer S and Vermorken
JB: Clinical and technical evaluation of ACS BR serum assay of MUC1
gene-derived glycoprotein in breast cancer, and comparison with CA
15-3 assays. Clin Chem. 43:585–593. 1997.PubMed/NCBI
|
|
21
|
Colomer R, Ruibal A, Genollá J, Rubio D,
Del Campo JM, Bodi R and Salvador L: Circulating CA 15-3 levels in
the postsurgical follow-up of breast cancer patients and in
non-malignant diseases. Breast Cancer Res Treat. 13:123–133.
1989.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Symeonidis A, Kouraklis-Symeonidis A,
Apostolopoulos D, Arvanitopoulou E, Giannakoulas N, Vassilakos P
and Zoumbos N: Increased serum CA-15.3 levels in patients with
megaloblastic anemia due to vitamin B12 deficiency. Oncology.
67:359–367. 2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Molina R, Auge JM, Farrus B, Zanón G,
Pahisa J, Muñoz M, Torne A, Filella X, Escudero JM, Fernandez P and
Velasco M: Prospective evaluation of carcinoembryonic antigen (CEA)
and carbohydrate antigen 15.3 (CA 15.3) in patients with primary
locoregional breast cancer. Clin Chem. 56:1148–1157.
2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Duffy MJ, Duggan C, Keane R, Hill AD,
McDermott E, Crown J and O'Higgins N: High preoperative CA 15-3
concentrations predict adverse outcome in node-negative and
node-positive breast cancer: Study of 600 patients with
histologically confirmed breast cancer. Clin Chem. 50:559–563.
2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Peng S, Huang P, Yu H, Wen Y, Luo Y, Wang
X, Zhou J, Qin S, Li T, Chen Y, et al: Prognostic value of
carcinoembryonic antigen level in patients with colorectal cancer
liver metastasis treated with percutaneous microwave ablation under
ultrasound guidance. Medicine (Baltimore). 97(e0044)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhao T and Hu W: CA125 and HE4:
Measurement tools for ovarian cancer. Gynecol Obstet Invest.
81:430–435. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zheng BH, Yang LX, Sun QM, Fan HK, Duan M,
Shi JY, Wang XY, Zhou J, Fan J, Ma ZY and Gao Q: A new preoperative
prognostic system combining CRP and CA199 for patients with
intrahepatic cholangiocarcinoma. Clin Transl Gastroenterol.
8(e118)2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen WZ, Shen JF, Zhou Y, Chen XY, Liu JM
and Liu ZL: Clinical characteristics and risk factors for
developing bone metastases in patients with breast cancer. Sci Rep.
7(11325)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kashyap D, Pal D, Sharma R, Garg VK, Goel
N, Koundal D, Zaguia A, Koundal S and Belay A: Global increase in
breast cancer incidence: Risk factors and preventive measures.
Biomed Res Int. 2022(9605439)2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Slimane K, Andre F, Delaloge S, Dunant A,
Perez A, Grenier J, Massard C and Spielmann M: Risk factors for
brain relapse in patients with metastatic breast cancer. Ann Oncol.
15:1640–1644. 2004.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Cao R and Wang LP: Serological diagnosis
of liver metastasis in patients with breast cancer. Cancer Biol
Med. 9:57–62. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hu J, Li G, Zhang P, Zhuang X and Hu G: A
CD44v subpopulation of breast cancer stem-like cells with enhanced
lung metastasis capacity. Cell Death Dis. 8(e2679)2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Brand RE, Nolen BM, Zeh HJ, Allen PJ,
Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD,
Vickers SM, et al: Serum biomarker panels for the detection of
pancreatic cancer. Clin Cancer Res. 17:805–816. 2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Stojkovic Lalosevic M, Stankovic S,
Stojkovic M, Markovic V, Dimitrijevic I, Lalosevic J, Petrovic J,
Brankovic M, Pavlovic Markovic A and Krivokapic Z: Can preoperative
CEA and CA19-9 serum concentrations suggest metastatic disease in
colorectal cancer patients? Hell J Nucl Med. 20:41–45.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Dayyani F, Uhlig S, Colson B, Simon K,
Rolny V, Morgenstern D and Schlumbrecht M: Diagnostic performance
of risk of ovarian malignancy algorithm against CA125 and HE4 in
connection with ovarian cancer: A meta-analysis. Int J Gynecol
Cancer. 26:1586–1593. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Tang S, Wei L, Sun Y, Zhou F, Zhu S, Yang
R, Huang Y, Zhang H, Xu H and Yang J: CA153 in breast secretions as
a potential molecular marker for diagnosing breast cancer: A meta
analysis. PLoS One. 11(e0163030)2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yuan Q, Song J, Yang W, Wang H, Huo Q,
Yang J, Yu X, Liu Y, Xu C and Bao H: The effect of CA125 on
metastasis of ovarian cancer: Old marker new function. Oncotarget.
8:50015–50022. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhou Y, Yu QF, Peng AF, Tong WL, Liu JM
and Liu ZL: The risk factors of bone metastases in patients with
lung cancer. Sci Rep. 7(8970)2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Lin Q, Chen XY, Liu WF, Zhu PW, Shi WQ, Li
B, Yuan Q, Min YL, Liu JM and Shao Y: Diagnostic value of CA-153
and CYFRA 21-1 in predicting intraocular metastasis in patients
with metastatic lung cancer. Cancer Med. 9:1279–1286.
2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kreusel KM, Wiegel T, Stange M, Bornfeld N
and Foerster MH: Intraocular metastases of metastatic breast
carcinoma in the woman. Incidence, risk factors and therapy.
Ophthalmologe. 97:342–326. 2000.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
41
|
Nelson CC, Hertzberg BS and Klintworth GK:
A histopathologic study of 716 unselected eyes in patients with
cancer at the time of death. Am J Ophthalmol. 95:788–793.
1983.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Demirci H, Shields CL, Chao AN and Shields
JA: Uveal metastasis from breast cancer in 264 patients. Am J
Ophthalmol. 136:264–271. 2003.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tarro G, Perna A and Esposito C: Early
diagnosis of lung cancer by detection of tumor liberated protein. J
Cell Physiol. 203:1–5. 2005.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lu F, Pan S, Qi Y, Li X and Wang J: The
clinical application value of RDW, CA153, and MPV in breast cancer.
Clin Lab. 67:2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Li X, Dai D, Chen B, Tang H, Xie X and Wei
W: Clinicopathological and prognostic significance of cancer
antigen 15-3 and carcinoembryonic antigen in breast cancer: A
Meta-analysis including 12,993 patients. Dis Markers.
2018(9863092)2018.PubMed/NCBI View Article : Google Scholar
|
